Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

about

Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis A time-and-motion approach to micro-costing of high-throughput genomic assays.Expression of Apoptosis Related and Proliferative Proteins in Malignant Lympho-Proliferative Disorders.

P2860

Q38257974-9304DB2D-1BD0-463E-9BF6-3E5355091929 Q40417191-EA66D2D2-1DDF-4050-B1DC-8BD87BCDC607 Q52358206-9B06E42C-309B-4160-A96F-045DBF599D31

P2860

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Item

http://www.wikidata.org/entity/Q37872044

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

@en

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances.

@nl

type

Item

label

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

@en

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances.

@nl

prefLabel

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

@en

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances.

@nl

P1476

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS

Control of regulatory T cell development by the transcription factor Foxp3

On the Origin of Cancer Cells

The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

p53 in health and disease

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

P2888

gm240

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/GM240

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Enrico Derenzini

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51098618

http://www.w3.org/2001/XMLSchema#string

P6179

1041538291

http://www.w3.org/2001/XMLSchema#string

P698

21542892

http://www.w3.org/2001/XMLSchema#string

P932

3129642

http://www.w3.org/2001/XMLSchema#string

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

about

P2860

P2860

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932